dexamethasone / Generic mfg. - LARVOL DELTA

Are there long-term effects of combination therapy for newly diagnosed adults with ITP? (PubMed, Br J Haematol) - "Three randomised controlled trials (2 dexamethasone (dex) vs. dexamethasone + rituximab (ritux), 1 mycophenolate mofetil (MMF) + steroids vs. steroids alone) and six single-arm trials (dex + ritux ± ciclosporin and dex + TPO-RA ± ritux) were analysed to determine the effects of combining these therapies. While short-term responses were promising, many studies lacked a longer follow-up past 1-1.5 years. The amount of ND patients who would have entered sustained response off therapy long term with no treatment/steroids only, as well as with combination therapy, is thus unknown and remains to be investigated."

Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

A First Report of the Misuse of a Novel Synthetic Glucocorticoid, 9α-Fluoro-6α-Methylprednisolone in Camel Racing. (PubMed, Drug Test Anal) - "During routine post-race drug testing of cameline plasma samples using liquid chromatography-tandem mass spectrometry we encountered an unknown peak with the same selected reaction monitoring traces as a dexamethasone formate adduct but at a different retention time...Therefore, the misuse of 9F6MP should be strictly controlled for the sake of animal welfare and the integrity of camel racing. The information described in this case report will be beneficial for other anti-doping laboratories in both human and animal sports for the purpose of doping control."

Journal

2-Hydroxyanthraquinone exposure causes the damage of cerebrovascular and blood brain barrier in zebrafish via inducing inflammation and downregulation of the Wnt/β-catenin signaling pathway. (PubMed, Comp Biochem Physiol C Toxicol Pharmacol) - "The co-administration of dexamethasone or BML-284 effectively rescued the cerebrovascular damage...This study reveals for the first time the adverse effects of 2-hATQ exposure on brain vascular development in aquatic organisms, suggesting that 2-hATQ and its ANT-related derivatives may be potential risk factors for cerebrovascular diseases. Our findings reveal, for the first time, that 2-hATQ impairs cerebrovascular and BBB development through concurrent induction of inflammation and suppression of the Wnt/β-catenin pathway, identifying these as critical mechanistic events in its toxicity."

Journal • CNS Disorders • Inflammation • Mood Disorders • Psychiatry • Vascular Neurology • DKK1 • IL1B • IL6 • TNFA • WIF1

Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC. (PubMed, Clin Lung Cancer) - "Among the 12 patients treated with escalating doses of quaratusugene ozeplasmid and standard doses of osimertinib there were 3 patients with prolonged time to progression, including 1 with continuing PR. Quaratusugene ozeplasmid administration was associated with a delayed infusion-related reaction managed with prophylactic steroids, acetaminophen and diphenhydramine. There were no DLTs. The recommended phase II dose of quaratusugene ozeplasmid in combination with osimertinib in patients with NSCLC progressing after osimertinib treatment is 0.12 mg/kg."

Journal • Gene Therapies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • EGFR • TUSC2

Endometrial Cell Senescence and Recurrent Spontaneous Abortion: Biomarker Potential of UCP2 and GSR. (PubMed, Reprod Sci) - "Drug prediction analysis highlighted dexamethasone and menadione as potential treatments. These insights suggest that oxidative stress-induced senescence plays a critical role in recurrent spontaneous abortion, with UCP2 and GSR as promising biomarkers and therapeutic targets to improve endometrial health and reduce miscarriage risk. Further clinical studies are needed to validate these findings and explore their therapeutic applications."

Biomarker • Journal

Effective front-line treatment of osteosclerotic myeloma with POEMS syndrome with daratumumab, lenalidomide and dexamethasone: a case report and literature review. (PubMed, Acta Clin Belg) - "Front-line treatment with daratumumab, lenalidomide, and dexamethasone (DRd) resulted in a rapid and durable clinical and biochemical response, including normalization of vascular endothelial growth factor levels. This improvement ultimately enabled the patient to successfully undergo ASCT.This case highlights the potential role of DRd as an effective induction strategy in functionally impaired patients with POEMS syndrome."

Journal • Endocrine Disorders • Hematological Malignancies • Monoclonal Gammopathy • Multiple Myeloma • Oncology • Pain • Rare Diseases • Transplantation

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Jerry Lee, MD, MSc, MPhil | Suspended ➔ Recruiting | Trial completion date: Nov 2027 ➔ Nov 2029

Enrollment open • Trial completion date • Hemophagocytic lymphohistiocytosis • Immunology • Rare Diseases

Deeper remission achievement and longer leukemia-free survival with inati-cel as consolidation therapy in allogeneic transplant-ineligible adolescent and adult patients with B-ALL (ASH 2025) - P1/2 | "All patients receivedlymphodepletion with fludarabine (30 mg/m2/d ×3 days) and cyclophosphamide (500 mg/m2/d×2 days) followed by Ina-cel infusion (0.6×108 live CAR-T cells)...Specially, only one patient had grade 3 CRS and grade 3 ICANS, characterized by high fever andhypotension, and was managed with tocilizumab in combination with dexamethasone (80 mg).Additionally, 7 patients (63.6%) suffered from cytopenia... Our preliminary results of the intervention study demonstrate inati-cel, a CD19 CAR-T celltherapy leads to high MRD-negativity conversion and survival rates with manageable toxicity intransplant-ineligible B-ALL patients. More patients are being enrolled and followed up. Long-termsurvival data are likely to support CD19 CAR-T cell therapy as a new paradigm for consolidation therapyfor B-ALL patients."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Transplantation

Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies (ASH 2025) - P1/2 | "This Phase I/II study (Study CCS1477-02) of Ino with pomalidomide and dexamethasone (InoPd) showed high response rates (75% ORR) with a manageable safety profile in heavily pre-treated relapsed/refractory multiple myeloma (RRMM), all of which were refractory to their last line of therapy. Serial blood and bone marrow samples are being collected for exploratory biomarker analysis to understand mechanisms of response to treatment or disease progression. These cohorts will be opened in approximately 8 sites in the UK and US."

Clinical • Combination therapy • IO biomarker • Metastases • P1/2 data • Hematological Malignancies • Multiple Myeloma • Myelodysplastic Syndrome • Oncology • IRF4

Convergence in age adjusted mortality rates and proportion of all deaths from COVID-19 among patients with hematologic malignancies, 2020-2024 (ASH 2025) - "One retrospective cohort study found no effect of immunosuppression with prednisone, tacrolimus, or mycophenolate mofetil on ventilation, in-hospital mortality or length of stay among hospitalized COVID-19 patients in one hospital system (Andersen et. There was a higher peak AAMR from COVID-19 as a proportion of all deaths in the general population during the heights of the COVID-19 pandemic (2020-2021) than among patients with HM as a share of all HM-associated deaths in the same period across all regions. The all-cause AAMR is higher at baseline among patients with HM, so the effect of COVID-19 may have been smaller in this population as a share of all deaths. Patients known to have HM may access care, take airborne precautions and vaccinate more regularly."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Solid Tumor

Real-world insights into multiple myeloma management: An analysis of EHR-derived data in the UK and Germany (ASH 2025) - "Most common first-line therapy was daratumumab, lenalidomide, and dexamethasone in Germany (13%), and cyclophosphamide, bortezomib, and dexamethasone (24%) in the UK. The UK and Germany cohorts included 616 and 466 patients, respectively. In both countries, 75% of patients were diagnosed at ISS stage II or III. Cytogenetic testing was reported for 59% of patients in Germany, compared to 60% of the UK cohort, with 1q21 gain/amplification and del13q being the most commonly reported positive tests in both countries."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Real-world step-up dosing of patients receiving elranatamab for multiple myeloma in Japan (ASH 2025) - "Almost all patients received dexamethasone during the SUD period (Group A: 192 [99.5%], Group A+B: 217 [99.5%]) and acetaminophen (Group A: 191 [99.0%], Group A+B: 216 [99.1%]). Other supportive medications received include diphenhydramine (Group A: 109 [56.5%], Group A+B: 124 [56.9%]) and tocilizumab (Group A: 101 [52.3%], Group A+B: 120 [55.0%])...Both the frequency and timing of CRS and ICANS were generally consistent with past findings from elranatamab clinical trials. Despite the occurrence of CRS and ICANS events, many patients continued to receive complete and timely SUD."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Inflammation • Multiple Myeloma

Temporal trends in treatment patterns and overall survival for multiple myeloma management in Taiwan using the national health insurance claims database (ASH 2025) - "Since then, treatment for MM has continued to evolve, most notably with availability of anti-CD38 monoclonal antibodies such as daratumumab (D). We investigated temporal trends in MM treatment patterns and clinical outcomes from 2013 to 2022, a period encompassing onset of reimbursement for lenalidomide (R) in first line (1L) in patients with transplant-ineligible (TI) MM from February 2020, and D for second line (2L) and beyond from April 2020...Between study periods, VTd use in 1L (approximately 50% of patients) was unchanged, use of V(bortezomib)R-dexamethasone(d) increased from 0-17.59%, and use of regimens containing melphalan and alkylators decreased... The NHIRD provides health insurance for the whole population of Taiwan, allowing complete and longitudinal data collection across all treatment settings. We observed increased uptake of novel agents after their reimbursement under the National Health Insurance that coincided with a decrease in attrition rates and an..."

Claims database • Clinical • Reimbursement • US reimbursement • Hematological Malignancies • Multiple Myeloma

Real-world survey of triplet versus quadruplet regimen preferences in transplant-ineligible (TIE) or deferred patients with newly diagnosed (ND) multiple myeloma (MM) (ASH 2025) - P3 | "Recently, data pertaining to anti-CD38 mAb-containing quadruplet regimens have been published (IMROZ: isatuximab ± bortezomib, lenalidomide, and dexamethasone [Isa-VRd]; NCT03319667 and CEPHEUS: daratumumab ± bortezomib, lenalidomide, and dexamethasone [Dara-VRd]; NCT03652064). The real-world data shows that Dara-VRd has emerged as the preferred regimen for non-frail, TIE/deferred patients with ND MM and that DRd is the preferred regimen for frail, TIE patients with ND MM. While interest for Isa-VRd saw a drastic increase for frail TIE patients with ND MM following review of the data, Dara-VRd was still the preferred anti-CD38 regimen if quadruplet regimens were considered. Despite the lack of a subgroup analysis of frail versus non-frail patients from CEPHEUS, Dara-VRd remains the preferred quadruplet therapy over Isa-VRd for TIE/deferred ND MM."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Transplantation

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy (ASH 2025) - "Background: The University of Pittsburgh Medical Center (UPMC) partnered with IntegraConnect to conduct a quality initiative (QI) studying the utilization of anti-CD38 agents and quadruplet (quad) therapy (lenalidomide, CD38, proteasome inhibitor and dexamethasone) in newly diagnosed multiple myeloma (NDMM), and how treatment selection has evolved throughout the QI project to date. The QI implemented at UPMC for LOT 1 MM treatment led to an improvement in utilization of CD38 therapy, overall quad based therapy, and quad-based therapy among quad-eligible patients. Incorporation of physician focus group educational sessions further increased adherence to best practices. Additional follow-up is needed to evaluate sustainability and patient outcome."

Clinical • Hematological Malignancies • Multiple Myeloma

Feasibility and safety of bispecific antibodies outpatient model in triple-refractory multiple myeloma patients in two Italian centers (ASH 2025) - "All patients underwent premedication with acetaminophen, chlorphenamine and dexamethasone during SUD and first full dose whereas three patients received post-medication with dexamethasone 16 mg the day after SUD1, SUD2 and first full dose...Seven patients were treated with teclistamab and one with talquetamab, approved after teclistamab in Italy...For both these two patients, tocilizumab was administered with rapid resolution of CRS and no need of hospitilization...A solid collaboration with emergency room doctors and nurses, the education of the patient and the outline of a path to rapidly and safely manage complications has been documented to be crucial. These encourage the feasibility of managing BSAbs therapy for MM patients in an outpatient setting in hub centres where multidisciplinary collaboration can be easily achieved."

Clinical • CNS Disorders • Hematological Disorders • Hematological Malignancies • Hypotension • Multiple Myeloma

Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States (ASH 2025) - "Treatment regimens were categorized into 7 mutually exclusive groups: bendamustine (B)-based chemotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without cytarabine), Bruton tyrosine kinase inhibitors (BTKi; covalent: zanubrutinib, acalabrutinib, ibrutinib, and non-covalent: pirtobrutinib), bortezomib (bort)-based, venetoclax (ven)-based, intensive chemotherapy (high-dose cytarabine, HyperCVAD (hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone, etc.), and other regimens (CAR-T or others). However, chemotherapy and/or immunotherapy were associated with the highest HCRU while BTKi were associated with the lowest HCRU. Notably, more than half of patients previously treated with BTKi and anti-CD20 therapies were subsequently treated with another covalent BTKi or a non-covalent BTKi, while approximately one-third received chemotherapy and/or immunotherapy, further emphasizing the need for novel..."

Clinical • HEOR • Real-world • Real-world evidence • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

Double trouble: The first reported case of evans syndrome following RSV Vaccination (ASH 2025) - "Her home medications included amlodipine, losartan, hydrochlorothiazide, and she reported receiving the RSV vaccine one week before admission...The patient was started on presumed ITP treatment with a 1g/kg dose of IVIG and high-dose dexamethasone 40 mg for 4 days...Due to refractory thrombocytopenia, the treatment was shifted to rituximab after the development of hemolytic anemia. The patient received a total of 4 doses weekly, along with a prednisone taper starting at 1 mg/kg, resulting in a slow improvement in her counts back to normal...Evans syndrome ideally requires multidisciplinary care and long-term monitoring due to its chronic, relapsing nature. This case highlights the importance of ongoing pharmacovigilance and educating physicians about immune-mediated hematologic complications that can occur post-vaccination, which are rare but potentially severe."

Clinical • Cardiovascular • Dyslipidemia • Hematological Disorders • Hematological Malignancies • Hepatology • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Primary Immunodeficiency • Respiratory Syncytial Virus Infections • Thrombocytopenia • HP

Evaluation of payment reimbursement models for teclistamab administration and monitoring in the community hospital setting (ASH 2025) - "Five doses of tocilizumab were given in model 1 and 0 doses were given in model 2 (p=0.26). Eight doses of supplemental dexamethasone were given in model 1 and 7 doses were given in model 2 (p=0.88)...Conclusion Outpatient model 1 had significantly higher payment reimbursement and net profit margins compared to inpatient model 2. Our study showed that site of care is an important consideration with BsAbs to optimize revenue and minimize costs, in addition to enhancing access among community-based practices."

Clinical • Reimbursement • US reimbursement • Hematological Malignancies • Multiple Myeloma

Analysis of the cost-effectiveness without compromising clinical outcomes in outpatient CD19-directed CAR-T therapy in non-Hodgkin lymphoma patients at a community-based medical center (ASH 2025) - "Secondary objectives included assessment of toxicity, response, and survival in patients receiving axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), or tisagenlecleucel (tisa-cel)...In 2024, one patient received prophylactic dexamethasone prior to infusion... Based on CMS data and the ZUMA-1 trial, the median inpatient stay for CAR-T therapy is approximately 15 days, with Medicare reimbursing an average of $498,700 per admission. This includes the high cost of the CAR-T product and the intensive inpatient care needed to manage toxicities like CRS and ICANS. In contrast, a typical 7-day inpatient hospital stay costs Medicare only $13,000 to $18,000."

Clinical • Clinical data • Cost effectiveness • HEOR • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma

Administration- and adverse event-related costs among patients with multiple myeloma treated with B-cell maturation antigen (BCMA)-targeted agents (ASH 2025) - " A 3-year BIM was developed to evaluate administration and AE-related costs for patients with RRMM and ≥1 prior line of therapy who had received belamaf plus bortezomib and dexamethasone (BVd), belamaf plus pomalidomide and dexamethasone (BPd), cilta-cel, ide-cel, or teclistamab. BVd/BPd had substantially lower administration and AE-related costs vs CAR-T and bispecific therapies, which have high costs mostly due to hospitalizations, premedication, and CRS rates."

Adverse events • Clinical • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

Comprehensive cost analysis of 4th line + therapies for relapsed/refractory multiple myeloma in Germany: Drug, co-medication, and office-based treatment perspective (ASH 2025) - "Whilst there is no official myeloma registry in Germany, treatments we considered were reimbursable combination therapies frequently used in the 4 th line treatment of RRMM in Germany in 2023, containing: carfilzomib, daratumumab, elotuzumab, melflufen, selinexor, talquetamab and teclistamab, and newly approved therapeutic options like elranatamab, along with evidence-based recommendations regarding premedication, comedication, and mandatory prophylaxis of treatment-related adverse events, as outlined in the Summary of Product Characteristics (SmPC) and published literature... Costs for myeloma drugs and combinations show a broad variation, from 88.863€ for Elotuzumab/Revlimid/Dexamethasone (ERd), to 178.850€ for talquetamab treatment. The second lowest in terms of annual costs was melflufen with 106.839€, followed by Elotuzumab/Pomalidomide/Dexamethasone (EPd):119.301€, teclistamab: 124.626€, Selinexor/Dexamethasone (Sd): 129.976€, elranatamab: 146.706€ and..."

Cost-analysis • HEOR • Hematological Malignancies • Multiple Myeloma

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient (ASH 2025) - "Complete remission (CR) was achieved after one cycle of melphalan/prednisone and local radiotherapy, but an abdominal relapse occurred six months later. Despite subsequent lines of therapy (bortezomib(bort)/lenalidomide(lena)/dexamethasone(dexa) and bendamustine/bort/dexa), the extramedullary multiple myeloma (MM) progressed. Remission was achieved after dexa/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE) and an autologous HCT performed on 1/2021...Allogeneic HCT was performed in 8/2022 after fludarabine/melphalan conditioning and anti-thymocyte globulin from a CCR5-Δ32homozygous, unrelated HLA-matched donor; cyclosporine/methotrexate was utilized as graft-versus-host diseas e (GVHD) prophylaxis... To our knowledge, this represents the first report of ART-free HIV RNA suppression following allogeneic HCT with a CCR5Δ32homozygous donor in an individual perinatally infected with HIV. Despite the differences in the latent reservoir and the mechanism..."

Clinical • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Multiple Myeloma • Plasmacytoma • Transplantation • CCR5 • CD4 • CD8

Aberrant lymphocytes are associated with increased inflammatory complications following CAR-T infusion (ASH 2025) - "CAR-T products included axi-cel (Yescarta) (n=10), brexu-cel (Tecartus) (n=2), liso-cel (Breyanzi) (n=1), tisa-cel (Kymriah) (n=1), or CD19-Car_Lenti (produced by the Officina Farmaceutica of Bambino Gesù Children's Hospital) (n=2)...Associations were not found between number of aberrant lymphocytes and development of neurotoxicity (eg, ICANS) nor with doses of Tocilizumab, Dexamethasone, or Anakinra or with WBC. While the number of patients is small, presence of increased aberrant lymphocytes, as pre-classified by the Scopio full-field digital morphology platform, appears to be associated with increased inflammatory complications following CAR-T infusion, including CRS of grade ≥2 and prolonged neutropenia requiring G-CSF support. Digital morphology combined with artificial intelligence may represent a novel platform for predicting clinical outcomes in CAR-T therapy."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Rheumatology

CAR t-cell therapy-related cytokine release syndrome and neurotoxicity: Real-world outcomes from a comprehensive cancer center (ASH 2025) - "Treatment options included ciltacabtagene autoleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel...Secondary outcomes included use of tocilizumab, corticosteroids, vasopressors, anakinra, intrathecal chemotherapy, dasatinib, and thiamine; length of stay; survival at 100 days and 1 year... 53 patients were included in the study. Most patients receiving axi-cel experienced grade 1 or 2 CRS, with only three patients experiencing grade ≥3 CRS. The incidence of CRS was lower here compared to ZUMA-1 and ZUMA-5."

CAR T-Cell Therapy • Clinical • Cytokine release syndrome • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology